



의료빅데이터의 개념, 현황, 활용전략

이화여대 의과대학 환경의학교실 김이준



강연자 소개

- ✓ 이화여대 의대 졸업
- ✓ 방사선종양학과 전문의
- ✓ 전 서울대학교병원 정밀의료센터 연구교수 (Big data, genomics)
- ✓ 전 이대목동병원 융합의학연구원 임상조교수 (Machine learning)
- ✓ 전 하버드의대 브리검여성병원 방문연구원 (Single cell sequencing)
- ✓ 현 이대의대 환경의학교실 조교수 (Wet lab & Dry lab)

지금까지 다루어 본 의료빅데이터

- 병원 임상 데이터
- 미국암등록사업데이터 (SEER)
- 건강보험공단데이터
- 심사평가원데이터
- CDW 데이터
- CDM 데이터
- TCGA 데이터 (RNA)
- GEO 데이터
- Bulk seq 데이터 (From Bcl files~)
- Single cell seq 데이터
- 등...








의료 빅데이터의 개념



What is big data?

| Value | Clinically relevant data Longitudinal studies |
|-------------|--|
| Volume | High-throughput technologies Continuous monitoring of vital signs |
| Velocity | High-speed processing for fast clinical decision support Increasing data generation rate by the health infrastructure |
| Variety | Heterogeneous and unstructured data sources Differences in frequencies and taxonomies |
| Veracity | Data quality is unreliable Data coming from uncontrolled environments |
| Variability | Seasonal health effects and disease evolution Non-deterministic models of illness and health |



Andreu-Perez et al. 2015 doi: 10.1109/JBHI.2015.2450362.





의료빅데이터의 종류

임상 데이터

- ✔정형
- ✓비정형
 - 줄글
 - 영상
 - 음성

유전체 데이터

- ✔DNA 돌연변이
- ✔RNA 유전체 발현량
- ✔단백질 발현량
- ✓Pharmacogenomics

Life-log 데이터

- ✔시계 심박동 체크
- ✔실시간 혈당 체크

사회적 데이터

- **✓**미세먼지
- ✔소셜 네트워크

유전체 데이터가 빅 데이터는 아니지 않 습니까??





왜 빅데이터의 시대가 도래하였는가?



컴퓨터 성능의 발전

- 메모리
- 프로세서
- 클라우드 시스템

정형 데이터의 전자화

- EMR
- 정부 데이터
- 병원간 데이터 (OMOP-CDM)

비정형 데이터의 정형화

- Natural Language Process (MLP)
- 영상 데이터 처리
- 음성 데이터 처리



데이터의 양은 왜 중요한가?

- ✔ 단순한 산술적인 다다익선 (多多益善)
 - 예전에는 모집단에 대한 표본 연구를 했었음
 - 이제는 모든 환자를 통계처리할 수 있음
 - 예. 미국 암환자등록사업(SEER)은 암환자는 의 무적으로 등록됨. 이 기록에서 특정 rare disease 환자 기록을 모두 사용한다면 미국내 모든 환자 기록을 활용하여 분석하는 것임.
 - 작은 sample size 의 한계가 없어.
 - 예. "연구 결과가 어떠한 경향성을 보이나 limitation of sample size 때문에 통계적 유의성 에 도달하지 못했다…"











빅데이터가 새로운 방식의 임상시험과 임상근거를 제시한다.



Real-world evidence (RWE), Real-world data (RWD)

Real-World Evidence



Real-world data (RWD) and real-world evidence (RWE) are playing an increasing role in health care decisions.

- FDA uses RWD and RWE to monitor postmarket safety and adverse events and to make regulatory decisions.
- The health care community is using these data to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice.
- Medical product developers are using RWD and RWE to support clinical trial designs
 (e.g., large simple trials, pragmatic clinical trials) and observational studies to
 generate innovative, new treatment approaches.

The 21st Century Cures Act, passed in 2016, places additional focus on the use of these types of data to support regulatory decision making, including approval of new indications for approved drugs. Congress defined RWE as data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials. FDA has expanded on this definition as discussed below.

Why is this happening now?

The use of computers, mobile devices, wearables and other biosensors to gather and store huge amounts of health-related data has been rapidly accelerating. This data holds potential to allow us to better design and conduct clinical trials and studies in the health care setting to answer questions previously though infeasible. In addition, with the development of sophisticated, new analytical capabilities, we are better able to analyze these data and apply the results of our analyses to medical product development and approval.

미국 FDA의 정의

What are RWD and where do they come from?

Real-world *data* are the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources. RWD can come from a number of sources, for example:

- Electronic health records (EHRs)
- · Claims and billing activities
- Product and disease registries
- Patient-generated data including in home-use settings
- Data gathered from other sources that can inform on health status, such as mobile devices

What is RWE?

Real-world **evidence** is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of RWD. RWE can be generated by different study designs or analyses, including but not limited to, randomized trials, including large simple trials, pragmatic trials, and observational studies (prospective and/or retrospective).


https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence





Relationship between sources of real world data and the ability to **control for confounding variables**


| Rank | 데이터 종류 |
|------|-------------------------|
| 1 | 장기 추적 관찰한 전향적 등록 데이터 |
| 2 | 다기관의 EMR 데이터 |
| 3 | 단일 기관의 EMR 데이터 |
| 4 | 보험청구데이터 (임상데이터셋과 연결 안된) |
| 5 | 설문조사 |
| 6 | 웨어러블 디바이스/SNS |




O'Leary et al. Diabetes, Obesity and Metabolism. 2020 Apr;22:3-12.



RCT 와 RWD/RWE



J Multidiscip Healthc. 2018;11:295-304




https://www.medpace.com/solutions/rwe-late-phase-clinical-research/



Balancing clinical evidence in the context of a pandemic

Nature Biotechnology volume 39, pages270–274 (2021)



"Indeed, in these modernized guidelines, some types of observational studies with striking effects now occupy the first or second tier of the levels-of-evidence pyramid."

a, Canadian Task Force on the Periodic Health Examination's Levels of Evidence (1979)

[.] Levels of evidence from Sackett (1989)

c, The Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence Working Group (March 2009)

d, OCEBM Levels of Evidence Working Group (2011



NEJM에 출판된 COVID-19 치료제 임상시험 결과들

| Trial | Patients (n) | Design | Results | Reference |
|---|--------------|---|---|-----------|
| Lopinavir-ritonavir in adults hospitalized with severe COVID-19 | 199 | Open-label RCT: Patients were randomly assigned in a 1:1 ratio to receive either lopinavir and ritonavir (400 mg and 100 mg, respectively; $n = 99$ patients) twice a day for 14 days in addition to standard care, or standard care alone ($n = 100$). The primary end point was the time to clinical improvement. | In hospitalized adult patients with severe COVID-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. | 7 |
| Compassionate use of remdesivir for patients with severe COVID-19 | 61 | Compassionate use: Remdesivir was provided to patients hospitalized with COVID-19 who had an oxygen saturation of ≤94% while breathing room air or who were receiving oxygen support. Patients received a 10-day course of remdesivir (200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment). | Clinical improvement was observed in 36 of 53 evaluable patients (68%). | 26 |
| HCQ | 1,376 | Observational study: HCQ (600 mg twice on day 1, then 400 mg daily for a median of 5 days). | In the main analysis, there was no significant association between HCQ use and intubation or death (hazard ratio, 1.04, 95% confidence interval (CI), 0.82 to 1.32). | 27 |
| HCQ | 821 | Double-blind RCT: Participants were randomly assigned in a 1:1 ratio to receive either HCQ (800 mg once, followed by 600 mg in 6 to 8 h, then 600 mg daily for 4 more days) ($N = 414$) or placebo ($n = 407$). The primary endpoint was incidence of either laboratory-confirmed COVID-19 or illness compatible with COVID-19 within 14 days. | The incidence of new illness compatible with COVID-19 was not significantly different between experimental arm (49 of 414, 11.8%) and control arm (58 of 407, 14.3%); the absolute difference was -2.4 percentage points (95% CI, -7.0 to 2.2 ; $P=0.35$). | 8 |
| Dexamethasone | 6,425 | Open-label RCT: Patients were randomly assigned to receive oral or intravenous dexamethasone (6 mg once daily; $n = 2,104$) for up to 10 days or to receive usual care alone ($n = 4,321$). The primary endpoint was 28-day mortality. | 482 patients (22.9%) in the dexamethasone group and 1,110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio (RR), 0.83; 95% CI, 0.75 to 0.93; $P < 0.001$). Among patients receiving invasive mechanical ventilation, the patients who received dexamethasone had a lower incidence of death compared to the usual care group (29.3% versus 41.4%; RR, 0.64; 95% CI, 0.51 to 0.81). The dexamethasone group compared with the usual care group had a lower incidence of death in those receiving oxygen without invasive mechanical ventilation (23.3% versus 6.2%; RR, 0.82; 95% CI, 0.72 to 0.94), but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; RR, 1.19; 95% CI, 0.91 to 1.55). | 10 |

Nature Biotechnology volume 39, pages270–274 (2021)







의료 빅데이터의 현황



최근 논문들...

건강보험공단 데이터 (NHIS, Claims) 등 빅데이터를 활용한 연구 (NHIS), 국내연구진

| Title | Methods | 비고 | Date | Journal | IF |
|---|--|--|--------------------|---------------------------|-------|
| Short-term exposure to PM10 and cardiovascular hospitalization in persons with and without disabilities: Invisible population in air pollution epidemiology | We conducted a time-stratified case-crossover analysis using conditional logistic regression to investigate the association between short-term exposure to PM₁₀ and cardiovascular hospital admissions. A case-crossover design is a variant of the matched case-control study, in which each case serves as his/her own control (Maclure, 1991). | 환경역학 Case-cross over design (like a matched case-control) Conditional logistic regression PM10 → cardiovascular hospitalization (Disability condition) | Novemb er 2022 | Sci. Total Environ. | 10.75 |
| Long-term opioid use and mortality in patients with chronic non-cancer pain: Ten-year follow- up study in South Korea from 2010 through 2019 | Owing to the large sample size, data of 2.5% of adult patients (≥20 years of age) were newly extracted using a stratified random sampling technique. Age and sex were used as an exclusive stratum for sampling. Next, we carried out survival analyses using multivariable Cox regression modelling for all-cause mortality factors spanning a 10-year period. | Random sampling technique Cox regression modelling Opioid use → mortality | Septemb er 2022 | EClinical Medicin e | 10.04 |



| Title | Methods | 비고 | Date | Journal | IF |
|--|---|---|-------------|-----------------------------|-------|
| Cardiovascular Implications of the 2021 KDIGO Blood Pressure Guideline for Adults With Chronic Kidney Disease | From the cross-sectional Korea National Health and Nutrition Examination Survey (KNHANES) and longitudinal National Health Insurance Service (NHIS) data, adults with nondialysis CKD were identified and categorized into 4 groups based on concordance/discordance between guidelines: 1) above both targets; 2) above 2021 KDIGO only; 3) above 2012 KDIGO or 2017 ACC/AHA only; and 4) controlled within both targets. We determined the nationally representative proportion and CVD risk of each group. | KNHANES (국민건강영양조사) – cross sectional NHIS (건강보험공단) - longitudinal CKD 환자군을 가이드라인 따라 4개군으로 분류 CKD → CVD (blood pressure) | May 2022 | J. Am. Coll. Cardiol. | 24.09 |
| Outcomes of living liver donors are worse than those of matched healthy controls | This <u>cohort study</u> included 12,372 LLDs who donated a <u>liver graft</u> between 2002 and 2018, and were registered in the Korean Network for Organ Sharing . They were compared to 3 matched control groups selected from the Korean NHIS and comprising a total of 123,710 individuals: healthy population (Group I); general population without comorbidities (Group II); and general population with comorbidities (Group III). | Cohort study 한국장기기증네트워크 3 matched control groups Liver donor → outcome | Nov 2021 | J. Hepatol. | 30.08 |
| Long-term Survival of 10,116 Korean Live Liver Donors | Data of 10,116 live liver donors were drawn from a mandated national registry of Korean live liver donors between 2000 and 2015. Matched controls were selected from the Korean National Health Insurance System-National Sample Cohort (NHIS-NSC). Median (range) follow-up of liver donors was 5.7 (0–15.9) years. Donors were 1:3 individually matched to controls by sex and 5-year age group ; potential controls were from the whole NHIS-NSC (Control 1) or from NHIS-NSC after excluding people with contraindications to be organ donors (Control 2) (donor, n = 7538; Control 1, n = 28,248; Control 2, n = 28,248). | 장기기증등록데이터 Matched control 을 건강보험공단 표 본코호트에서 생성 Liver donor → survival | Aug 2021 | Ann. Surg. | 13.79 |

| | | | | (EE) | ೧) ಕೆಓಡು ಸ |
|--|---|---|-----------------------|---------------------------------|------------|
| Title | Methods | 비고 | Date | Journal | IF |
| Incidence of cancer after asthma development: two independent population-based cohort studies | Two independent, population-based, longitudinal cohorts were examined, and estimated hazard ratios were determined using Cox regression. One group consisted of an unmatched cohort of 475,197 participants and a propensity score—matched cohort of 75,307 participants from the National Health Insurance Service—National Sample Cohort (NHIS-NSC; claims-based data from 2003 to 2015). The other group consisted of 5,440 participants from the Ansan-Ansung cohort (interview-based data from 2001 to 2014). | # 2개의 longitudinal cohorts • 건강보험공단 표본코호트 (matched-control) • 안산-안성 코호트 (인터뷰 기반) • Asthma → cancer | May 13, 2020 | J. Allergy Clin. Immunol. | 14.29 |
| Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population | A total of 246 459 oral anticoagulant-naïve non-valvular AF patients were enrolled from Korea National Health Insurance Service (NHIS) database (2005–2015). The risk of ischaemic stroke according to the duration of hypertension and systolic BP (SBP) levels were assessed. | 건강보험공단의 AF patients cohort study Ischaemic stroke risk AF → ischemic stroke (hypertension duration, blood pressure) | January 2019 | Eur. Heart J. | 35.86 |
| Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study | Health checkup data of 17,163,560 individuals aged ≥40 years provided by the National Health Insurance Service (NHIS) of South Korea between January 1, 2009, and December 31, 2012, were included, and participants were followed up until December 31, 2015. The mean follow-up duration was 5.3 years. The hazard ratio (HR) and 95% confidence interval (CI) of PD were estimated using a Cox proportional hazards model adjusted for potential confounders. | 건강보험공단의 건강검진 데이터 Cox proportional hazard ratio Metabolic syndrome → Parkinson | August 21, 2018 | PLoS Med | 11.61 |
| Cumulative Dose Threshold for the Chemopreventive Effect of Aspirin Against Gastric Cancer | • A total of 461,489 individuals in a population-based longitudinal cohort provided by the National Health Insurance Services (NHIS) in the Republic of Korea were observed from 2007 to 2012 to identify gastric cancer incident cases. The pharmacy claims data of these individuals from 2002 to 2006 were reviewed to assess cumulative medication exposure using the defined daily dose (DDD) system. Hazard ratios (HRs) of aspirin use for gastric cancer were estimated using multivariate Cox Proportional Hazard regression. Sensitivity analyses, including propensity-score matching and a nested case-control design, were performed to evaluate the variability caused by study design. | Cohort study Defined daily dose (DDD) system Multivariate Cox proportional hazard regression # Sensitivity analysis (study design) Propensity score matching Nested case-control design Aspirin → Gastric cancer (preventive) | June 2018 | Am. J. Gastroen terol | 10.38 |

| Title | Methods | 비고 | Date | Journal | IF |
|---|--|--|-------------|------------------|-------|
| Gamma-glutamyl transferase predicts future stroke: A Korean nationwide study | In Korea, the National Health Insurance Service (NHIS) provides full-coverage health insurance service for all citizens. Using data from the NHIS, the NHIS-National Sample Cohort was designed by randomly selecting 2% of Koreans, carefully considering demographic characteristics. We analyzed eligible individuals from this standardized cohort. The Cox proportional hazards model was used for the study investigating the relationship between GGT and stroke. Sex, age, and measurements of height, weight, systolic blood pressure, fasting blood glucose, total cholesterol, hemoglobin, aspartate transaminase (AST), alanine transaminase (ALT), and GGT were routinely obtained for all participants at the time of their first general health examination. | 건강보험공단 표본코호트 건강검진자료 Cox proportional hazard ratio Gamma-glutamyl transferase → stroke (predictive) | Feb 2018 | Ann. Neurol. | 10.42 |
| Weight gain after smoking cessation does not modify its protective effect on myocardial infarction and stroke: evidence from a cohort study of men | A prospective cohort study using the National Health Insurance Service (NHIS) data set collected from 2002 to 2013 was implemented. Based on the first (2002–03) and second (2004–05) NHIS health check-up periods, 108 242 men aged over 40 years without previous diagnoses of MI or stroke were grouped into sustained smokers, quitters with BMI gain, quitters without BMI change, quitters with BMI loss, and non-smokers. | Prospective cohort study 건강검진 데이터 Grouping Smoking cessation → MI (protective) (Weight gain) | Jan 2018 | Eur. Heart J. | 35.86 |
| Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea | We included 366 507 subjects (age ≥20 years) not diagnosed with non-valvular AF from the Korean National Health Insurance Service-National Sample Cohort (NHIS-NSC) from 2003 to 2008. In total, 139 306 subjects diagnosed with AF-related comorbidities were excluded, and a 227 102 healthy population was followed up until 2013. The body mass index (BMI), blood pressure (BP), and fasting blood glucose (BG) level were acquired during National health check-ups. | 건강보험 표본코호트 건강검진 Cohort study Impaired fasting glucose, prehypertension – AF | Sep 2017 | Eur. Heart J. | 35.86 |

| A OI OLO | | | | | ᆡᅌᇈᄺᆠᇆᆙᄒ |
|---|---|---|--------------|--------------------|----------|
| Title | Methods | 비고 | Date | Journal | IF |
| Association of prediabetes with death and diabetic complications in older adults: the pros and cons of active screening for prediabetes | a total of 36,946 adults aged ≥65 years who underwent national health examinations from 2006 to 2008. follow-up was until 31 December 2015. Cox's proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for death and diabetic complications. | 건강검진자료 Cox proportional HR Prediabetes → death, diabetic complications | June 2022 | Age Ageing | 10.67 |
| Association of Chronic Hepatitis B Infection and Antiviral Treatment With the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study | We conducted an 18-month landmark analysis using nationwide claims data from the National Health Insurance Service of South Korea. Patients newly diagnosed with CHB in 2012-2014 (n = 90,944) and matched-controls (n = 685,436) were included. Patients with CHB were further classified as the NA-treated (CHB+/NA+, n = 6,539) or the NA-untreated (CHB+/NA-, n = 84,405) group. Inverse probability of treatment weighting analysis was applied to balance the treatment groups. Time-varying Cox analysis was performed to evaluate time-varying effect of NA treatment . The primary outcome was the development of any primary extrahepatic malignancy . Development of intrahepatic malignancy and death were considered as competing events . | Matched-control Inverse probability of treatment weighting analysis Time-varying Cox analysis Chronic hepatitis B infection → Extrahepatic malignancy (Antiviral treatment) | May 2022 | J. Clin. Oncol. | 44.54 |
| Leukotriene-receptor antagonist and risk of neuropsychiatric events in children, adolescents, and young adults: a self- controlled case series | A self-controlled case series study was conducted using the Korean National Health Insurance Service claims database from two three-year observation periods (observation period 1 [Obs1]: 2005 to 2007, observation period 2 [Obs2]: 2016 to 2018). Asthma or AR patients aged 3–30 years who were prescribed LTRAs and diagnosed with NPEs were included. The incidence rate ratios (IRRs) for exposed period and risk periods (1–3, 4–7, 8–14, 15–30, 31–90, >90 days from initiation of LTRA) compared to unexposed periods were calculated using conditional Poisson regression . Subgroup analysis according to age group, type of NPEs and indication of LTRA was performed. | Self-controlled case series Incidence rate ratio – conditional Poisson regression Subgroup analysis Leukotriene-receptor antagonist → neuropsychiatric events (children, adolescents, young adults) | May 2022 | Eur. Resp. J. | 33.80 |

| | Title | Methods | Н | 고 | Date | Journal | IF | 대학교 |
|------|--|---|---|--|-----------------|---|-------|------------|
| | Risk of COVID-19 Infection and of Severe Complications Among People With Epilepsy A Nationwide Cohort Study | We included participants who underwent at least 1 severe acute respiratory syndrome coronavirus 2 real-time reverse-transcription PCR test between January 1 and June 4, 2020, from the Korean nationwide COVID-19 dataset . Epilepsy was defined according to the presence of diagnostic code in health claims data before the COVID-19 diagnosis. To investigate the association between epilepsy and the susceptibility for or severe complications of COVID-19, a 1:6 ratio propensity score matching (PSM) and logistic regression analysis were performed. Severe complications with COVID-19 infection were defined as a composite of the incidence of mechanical ventilation, intensive care unit admission, and death within 2 months after COVID-19 diagnosis. | • | 한국 COVID 데이터셋 건강보험공단자료 연계 Propensity score matching COVID-19 → Complications (with Epilepsy) | March 2022 | Neurol ogy | 11.80 | university |
| | Risk of Incident Dementia According to Glycemic Status and Comorbidities of Hyperglycemia: A Nationwide Population- Based Cohort Study | Using a health insurance claims database and the results of biennial health examinations in South Korea, we selected 8,400,950 subjects aged ≥40 years who underwent health examinations in 2009–2010. We followed them until 2016. Subjects' baseline characteristics were categorized by presence of diabetes (yes/no) and glycemic status as normoglycemia, impaired fasting glucose (IFG), new-onset diabetes, or known diabetes (duration <5 years or ≥5 years). We estimated adjusted hazard ratios (aHRs) for dementia occurrence in each category. | • | 건강보험공단자료 건강검진데이터 Adjusted hazard ratio Diabetes → Dementia | October 2021 | Diabete s Care | 19.11 | |
| | High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases | Using data from the Korean National Health Insurance claims database gathered between 2007 and 2016, we calculated the incidence rate ratios (IRRs) of vertebral and hip fractures in patients with newly diagnosed IBD (n = 18,228; 64.1% male, 65.9% ulcerative colitis) compared with an age- and sex-matched control population (matching ratio, 1:10; n = 186,871). | • | Incidence rate ratio (IRR) Matched control IBD → Fracture | June 2021 | Clin. Gastroe nterol. Hepatol. | 11.38 | |
| | Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout | Using the Korean National Health Insurance claims data (2002–17), we conducted a cohort study of 124 434 gout patients who initiated either allopurinol (n = 103 695) or benzbromarone (n = 20 739), matched on propensity score at a 5:1 ratio. The primary outcome was a composite CV endpoint of myocardial infarction, stroke/transient ischaemic attack, or coronary revascularization. To account for competing risk of death, we used cause-specific hazard models to estimate hazard ratios (HRs) and 95% confidence intervals (Cls) for the outcomes comparing allopurinol initiators with benzbromarone. | • | Matched control (PSM) Cause-specific hazard model Allopurinol vs. Benzbromarone → Cardiovascular risk | Sep 2021 | Eur. Heart J. | 35.86 | |
| RE . | Impact of smoking on the development of idiopathic pulmonary fibrosis: results from a nationwide population- based cohort study | Using the Korean National Health Information Database, we enrolled individuals who had participated in the health check-up service between 2009 and 2012. Participants having a prior diagnosis of IPF were excluded. The history of smoking status and quantity was collected by a questionnaire. We identified all cases of incident IPF through 2016 on the basis of ICD-10 codes for IPF and medical claims. Cox proportional hazards models were used to calculate the adjusted HR (aHR) of the development of IPF. | • | 건강보험공단 건강검진 Cox proportional hazard ratio Smoking → idiopathic pulmonary fibrosis | Sep 2021 | Thorax | 10.31 | 19 |

| | | | | (F=0) | 이하여자대학교 |
|--|--|---|--------------|---------------------------------|-----------|
| Title | Methods | 비고 | Date | Journal | IF ERSITY |
| Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study | While some recent studies have reported the development of tuberculosis (TB) in patients exposed to immune checkpoint inhibitors (ICIs), there is limited evidence to date. Therefore, we evaluated the risk of TB in patients with cancer exposed to ICIs using the National Health Insurance claims data in South Korea. Patients with diagnostic codes for non-small cell lung cancer, urothelial carcinoma or melanoma between August 2017 and June 2019 were identified. The incidence rate and standardized incidence ratio (SIR) of TB were calculated for both the ICI exposure and non-exposure groups. The risk of TB according to ICI exposure was assessed using a multivariable Cox regression model. | Incident rate, strandardized incidence ratio (SIR) ICI exposure group vs non-exposure group Multivariate Cox regression Immune check point inhibitor → TB | Sep 2021 | J. Immuno ther. Cancer | 12.47 |
| Awareness of the use of hyponatraemia-inducing medications in older adults with hyponatraemia: a study of their prevalent use and association with recurrent symptomatic or severe hyponatraemia | To evaluate the use of hyponatraemia-inducing medications (HIMs) after treatment for symptomatic or severe hyponatraemia and to investigate the impact of HIMs on the recurrence of symptomatic or severe hyponatraemia in older patients. A cross-sectional and nested case—control study using data obtained from national insurance claims databases. The rate of prescribing HIMs during the 3 months before and after the established index date was analysed in a cross-sectional analysis. Multivariable logistic regression was performed to investigate the association between HIM use and recurrence of symptomatic or severe hyponatraemia after adjusting for covariates in a case—control study. | Cross-sectional: prescription rate before and after hyponatraemia diagnosis Nested case-control study: hyponatraemia recurrence rate, Multivariate logistic regression Hyponatraemia-inducing medication with hyponatraemia → recurrence of hyponatraemia | July 2021 | Age Ageing | 10.67 |
| Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population- based cohort study | Using the Korean nationwide claims and health examination database, we included subjects who were newly diagnosed with AF between 2010 and 2016. Patients were categorized into three groups according to the status of alcohol consumption before and after AF diagnosis: non-drinkers; abstainers from alcohol after AF diagnosis; and current drinkers. The primary outcome was incident ischaemic stroke during follow-up. Non-drinkers, abstainers, and current drinkers were compared using incidence rate differences after the inverse probability of treatment weighting (IPTW). | 건강보험공단 데이터 건강검진 데이터 3 groups according to alcohol consumption Incidence rate differences IPTW AF → ischaemic stroke (alcohol consumption, abstainer) | June 2021 | Eur. Heart J. | 35.86 |

| | v® ol¢tot | | | | |
|--|---|---|-----------------------|------------------------------|---------|
| Title | Methods | 비고 | Date | Journal | IF ISIT |
| Risk of Hematologic Malignant Neoplasms From Abdominopelvic Computed Tomographic Radiation in Patients Who Underwent Appendectomy | This nationwide population-based cohort study used the National Health Insurance Service claims database in South Korea to assess 825 820 patients who underwent appendectomy for appendicitis from January 1, 2005, to December 31, 2015, and had no underlying risk factors for cancer. Patients were divided into CT-exposed (n = 306 727) or CT-unexposed (n = 519 093) groups. The study was terminated on December 31, 2017, and data were analyzed from October 30, 2018, to September 27, 2020. | CT-exposed vs. CT-unexposed Abd CT (appendectomy) → Hematologic malignant neoplasm | January 20, 2021 | JAMA Surg. | 16.68 |
| Effect of Asthma and Asthma Medication on the Prognosis of Patients with COVID-19 | The study included 7590 de-identified patients, who were confirmed to have COVID-19 using the severe acute respiratory syndrome coronavirus 2 RNA-PCR tests conducted up to May 15, 2020; we used the linked-medical claims data provided by the Health Insurance Review and Assessment Service. Asthma and asthma severity (steps suggested by the Global Initiative for Asthma) were defined using the diagnostic code and history of asthma medication usage. | COVID-19 data 연계 건강보험데이터 Asthma, asthma medication → Prognosis of COVID-19 | September 25, 2020 | Eur. Resp. J. | 16.67 |
| Altered Risk for Cardiovascular Events With Changes in the Metabolic Syndrome Status: A Nationwide Population-Based Study of Approximately 10 Million Persons | A total of 27 161 051 persons who received national health screenings from 2009 to 2014 were screened. Those with a history of major adverse cardiovascular events (MACE) were excluded. We determined the MetS status of 9 553 042 persons using the following harmonizing criteria: MetS-chronic (n = 1 486 485), MetS-developed (n = 587 088), MetS-recovery (n = 538 806), and MetS-free (n = 6 940 663). | 건강검진 데이터 Metabolic syndrome 에 따른 group 분류 Metabolic syndrome → Cardiovascular event | November 2019 | Ann. Intern. Med. | 51.6 |
| Nasal Polyps and Future Risk of Head and Neck Cancer: A Nationwide Population-based Cohort Study | The 2005-2017 National Health Insurance claims and National Health Screening program databases were used to construct a cohort of patients with nasal polyps and matched comparators in Korea. The relative risk of NCPS and nasopharyngeal cancer in patients with nasal polyps was examined. | Matched coparators Nasal polyps → Head and neck cancer | July 2019 | J. Allergy Clin. Immunol. | 14.29 |

🙉 이화여자대학교

| Title | Methods | 비고 | Date | Journal | IF SIT |
|---|--|---|----------------------|----------------------|--------|
| Markedly Reduced Risk of Internal Malignancies in Patients With Vitiligo: A Nationwide Population-Based Cohort Study | We conducted a population-based retrospective cohort study using data from the Korean National Health Insurance claims database obtained from January 2007 to December 2016. All patients age 20 years or older with vitiligo who had at least two contacts with a physician from 2009 to 2016, during which a principal diagnosis was made, were identified (vitiligo group). Controls were randomly selected (two per patient with vitiligo) after frequency matching with the vitiligo group for age and sex during the same period (control group). | Cohort study Vitiligo → internal malignancies Matched control | Februa ry 2019 | J. Clin. Oncol. | 44.54 |
| Antithyroid Drugs and Congenital Malformations: A Nationwide Korean Cohort Study | A cohort of 2 886 970 completed pregnancies linked to live-born infants in 2 210 253 women between 2008 and 2014 in NHIS (Nationwide cohort study). The risk for overall and organ-specific congenital malformations in offspring, with logistic regression models used to control for potential confounders. | 산모/신생아 코호트 Logistic regression Antithyroid drug → Congenital malformation | Januar y 2018 | Ann. Intern. Med. | 51.6 |
| High liver fibrosis index FIB-4 highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers | Our retrospective cohort study involved 986 Korean HBsAg carriers 40 years of age or older who visited Seoul National University Hospital for a health checkup. National medical service claims data were used to determine HCC incidence. Median follow-up time was 5.4 years (interquartile range: 4.4 years). | 병원 건강검진 자료와 NHIS 의 HCC 진단 자료를 연계함. FIB-4 index → HCC | DEC 2014 | Hepatology | 17.42 |
| Job Loss and Re- Employment of Cancer Patients in Korean Employees: A Nationwide Retrospective Cohort Study | All employees except for the self-employed in Korea who were diagnosed with cancer during the 2001 calendar year (n=5,396) were identified as the first baseline patients and were followed every 3 months over 6 years to estimate the time taken to job loss. Patients who lost their job within the first year after a diagnosis of cancer (n=1,398) were identified as the second baseline patients and were followed up over 5 years to estimate the time taken to re-employment using the National Health Insurance claims data . Patient demographic, socioeconomic, and clinical variables were investigated as factors that affected job loss and re-employment. | Cancer 진단 후 job loss Job loss 후 re- employment 사회과학적 분야 연구 | March 2008 | J. Clin. Oncol. | 44.54 |

| A OI OLOTALTHE | | | | | | |
|--|---|---|------------------|---------------------------------|-------|--|
| Title | Methods | 비고 | Date | Journal | IF | |
| Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011) | This study investigated whether sarcopenia is associated with significant liver fibrosis in subjects with NAFLD. Data from the Korean National Health and Nutrition Examination Surveys 2008-2011 database were analyzed. | Sarcopenia → liver fibrosis (Nonalcoholic fatty liver disease) | December 2015 | Hepatology | 17.42 | |
| Low vitamin D levels are associated with atopic dermatitis, but not allergic rhinitis, asthma, or IgE sensitization, in the adult Korean population | A cross-sectional study was performed by using data collected from 15,212 individuals 19 years or older who participated in the Korean National Health and Nutrition Examination Survey from 2008 to 2010. | Cross sectional study Vitamin D → atopic dermatitis | January 2014 | J. Allergy Clin. Immunol. | 14.29 | |





의료 빅데이터의 활용전략








글로벌 CDM network


OMOP-CDM (Common data model)







한국의 CDM network





전략 - Big data가 어디에 있는지 알아야

- ✓ 직접 구축한 병원 cohort
- ✔ 공개 빅데이터들 (국내)
 - 건강보험데이터
 - 심사평가원데이터
 - 국민건강영양조사
- ✔ 공개 빅데이터들 (국제)
 - 미국/영국 등 공개 데이터
 - 우리 과의 international association 에서 구축한 공개 코호트



전략 - 데이터 선택 시 고려할 점

- ✔ 내 연구를 하기에 가장 효과적인 데이터는 무엇인가?
- ✓ 내가 관심있는 value가 포함되어 있는가?
- ✓ Longitudinal 인가, 아니면 cross-sectional 인가?
- ✔ 공신력 있는 데이터인가?
- ✓ 여러 cohort를 해볼 것인가? (2개?)



전략 - 어떤 주제의 연구를 하고 싶은지?

- ✓ 결국 중요한 것은 domain knowledge
- ✔ 진료를 보면서 떠올랐던 궁금증, 연구 주제들
- ✔ 문헌 검색
- \checkmark A \rightarrow new B
- ✓ New A → B (other disease, drug, biomarker...)
- \checkmark A \rightarrow B (new sub-condition?)



전략 - 그 연구를 하기 위한 연구 디자인?

- Evidence pyramid
- Cohort study
- ✓ Matched case-control (propensity score matching, IPTW)
- Cross sectional



전략 – 효과적인 통계 기법은 무엇인지?

- ✔ 문헌 검색
- ✔ 통계 자문 구하기



전략 – target journal 은 무엇인지?

- ✔ Observational study 에서 STROBE 기준을 고려하면서 연구 setting
- ✓ Target journal 들이 내가 생각하는 연구 주제에 관심이 있는지? (scope 고려)
- 이미 출판된 최근 논문들의 기법과 수준을 확인





누가 분석을 할 것인지?

- ✓ 직접 한다.
 - R programming
 - SAS
 - Python

- ✓ 공동 연구자(분석자)와 함께 한다.
 - 어떻게 구하는가?
 - 공동 연구자 찾기
 - 병원 분석 지원
 - 연구원 채용
 - 학생과 함께
 - 이 때 본인(PI)의 역할은 무엇인가?
 - 연구 주제 선정
 - 연구 디자인
 - 연구를 위한 빅데이터 마련 (IRB, 데이터 신청, 데이터 조건 설정, 조작적 정의 지정, 데이터 신청 비용을 위한 연구비 수주 등), 결과 분석, 논문 작성, 논문 투고 등...
 - 사실 할 일이 매우 많음...
 - 프로그래밍 돌리는 것 빼고 모두 다 본인이 할 일임





연구 기법의 발전


닥터 배의 술술보건의학통계 SPSS




이제 R 프로그래밍이 기본



AI 도 이젠 해야 해 Python 할 줄 알아야... 통계기법의 하나로 자리잡을 예정...





```
aucs = []
    mean_fpr = np.linspace(0, 1, 100)
    # X_train, X_test, y_train, y_test = train_test_split(df_SNUH2.to_numpy(), df_SNUH['death30'].to_numpy(), test_size=0.33, random_state=42)
    # X = df_SNUH2.to_numpy()
    # Y = df_SNUH['death30'].to_numpy()
    for i, (train, test) in enumerate(kfold.split(X, Y)):
        model_SNUH.fit(X[train], Y[train])
        viz = plot_roc_curve(model_SNUH, X[test], Y[test],
                            name='ROC fold {}'.format(i).
                             alpha=0.3, lw=1, ax=ax)
        interp_tpr = np.interp(mean_fpr, viz.fpr, viz.tpr)
        interp tor[0] = 0.0
        tprs.append(interp tpr)
        aucs.append(viz.roc auc)
    ax.plot([0, 1], [0, 1], linestyle='--', lw=2, color='r',
            label='Chance', alpha=.8)
    mean_tpr[-1] = 1.0
    mean_auc = auc(mean_fpr, mean_tpr)
    std_auc = np.std(aucs)
            label=r'Mean ROC (AUC = %0.3f $\pm$ %0.3f)' % (mean_auc, std_auc),
    std_tpr = np.std(tprs, axis=0)
    tprs_upper = np.minimum(mean_tpr + std_tpr, 1)
    tprs_lower = np.maximum(mean_tpr - std_tpr, 0)
    ax.fill_between(mean_fpr, tprs_lower, tprs_upper, color='grey', alpha=.2,
                    label=r'$\pm$ 1 std. dev.')
    ax.set(xlim=[-0.05, 1.05], vlim=[-0.05, 1.05],
         title="Receiver operating characteristic")
    ax.legend(loc='center_left', bbox to anchor=(1, 0.5))
Automatically created module for IPython interactive environment
                                                               ROC fold 1 (AUC = 0.98
                                                               ROC fold 2 (AUC = 0.95
                                                               ROC fold 3 (AUC = 0.94
                                                               ROC fold 4 (AUC = 0.91
                                                               ROC fold 5 (AUC = 0.97)
                                                               ROC fold 6 (AUC = 0.96)
                                                               ROC fold 7 (AUC = 0.94
                                                               ROC fold 8 (AUC = 0.96)
                                                               ROC fold 9 (AUC = 0.96)
                                                            Mean ROC (AUC = 0.954 ± 0.020)
                                                            ± 1 std. dev.
                     0.2 0.4 0.6 0:
False Positive Rate (Positive label: 1)
```




학습 빅데이터가 넘쳐나는 세상

- ✓ 국내 무료/유료 강좌
- ✓ 대학 공개강좌 (MIT, Stanford)
- ✓ Stack Overflow
- ✓ (Almost) 모든 것이 공개되어 있어
- ✓ 사람들 간의 <mark>초격차</mark>가 가능한 세상



- Q. 왜 정보를 공유할까?
- 데이터를 공개함으로써 오히려 영향력 증가
- Citation number is the power.
- "Like" is the power. : 구독과 좋아요!







Thank you!

yijunkim@ewha.ac.kr